Net Zero Festival: Schroders' Maria Teresa Zappia on investing in nature-based solutions

BusinessGreen staff
clock • 1 min read

VIDEO: Asset manager's chief impact and blended finance officer - and deputy CEO of BlueOrchard - chats to BusinessGreen's James Murray ahead of the Net Zero Festival

Maria Teresa Zappia is chief impact and blended finance officer at Schroders, UK-based investor which manages over £773bn of assets on behalf of institutional and retail investors, financial institutions and high-net-worth clients from around the world.

In addition, Zappia is the deputy CEO of BlueOrchard, the microfinance specialist in which Schroders holds a majority stake. 

Sitting down recently for a chat with BusinessGreen editor-in-chief James Murray ahead of the upcoming Net Zero Festival, Zappia offers her take on the growing investment market for nature-based solutions, what it means in practice to invest in forestry and nature restoration projects, and how Schroders plans to continue growing and scaling up its interests in this critical area in support of net zero.

The conversation can be watched above.

Schroders is a partner of the Net Zero Festival.

More on Investment

National Wealth Fund provides £300m loan guarantee to Haweswater Aqueduct Resilience Programme

National Wealth Fund provides £300m loan guarantee to Haweswater Aqueduct Resilience Programme

Rachel Reeves hails deal as evidence of how new government-backed fund is catalysing investment and enhancing climate resilience

James Murray
clock 22 August 2025 • 2 min read
Survey: Younger people leading drive towards greener pensions

Survey: Younger people leading drive towards greener pensions

OVO-commissioned study reveals under 35s are nearly three times more likely than those over 65 to know exactly where their pension is invested

BusinessGreen staff
clock 21 August 2025 • 2 min read
Meatable acquires Uncommon's cultivated meat platform

Meatable acquires Uncommon's cultivated meat platform

Lab grown meat pioneer pledges to progress and scale up Uncommon Bio's alternative protein innovation, after Cambridge-based firm shifts focus to therapeutic products

Stuart Stone
clock 21 August 2025 • 4 min read